glucagon-like peptide-1 Report issue

Biologics Peptide Experimental
AACT PubChem

Active Ingredient History

NOW
  • Now
Glucagon-like peptide-1 (GLP-1) is a 30- or 31-amino-acid-long peptide hormone deriving from the tissue-specific posttranslational processing of the proglucagon peptide. It is produced and secreted by intestinal enteroendocrine L-cells and certain neurons within the nucleus of the solitary tract in the brainstem upon food consumption. The initial product GLP-1 (1–37) is susceptible to amidation and proteolytic cleavage, which gives rise to the two truncated and equipotent biologically active forms, GLP-1 (7–36) amide and GLP-1 (7–37). Active GLP-1 protein secondary structure includes two α-helices from amino acid position 13–20 and 24–35 separated by a linker region.   Wikipedia

Chemistry

  • SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)O)C(C)C
  • InChIKey: UCZDWGAJSOUHOU-VDBPWWIZSA-N
  • Mol. Mass: 3169.55
  • ALogP: Missing data
  • ChEMBL Molecules:
    glp-1  
    glucagon-like peptide 1  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

glp-1 | glucagon like peptide-1 | glucagon-like peptide-1

Organizations (39)

Research & Development (39)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (19)

Approved Indications (1)


 

Obesity

Experimental Indications - Clinical Trial Phases 1-4 (18)


 

Bariatric Surgery (Early Phase 1)

Blood Glucose (Phase 1/Phase 2)

Coronary Disease (Phase 4)

Critical Illness (Phase 2)

Diabetes Mellitus (Phase 1)

Diabetes Mellitus, Type 1 (Early Phase 1)

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 2/Phase 3)

Heart Failure (Phase 1)

Hemorrhage (Phase 1/Phase 2)

Hyperglycemia (Phase 1)

Hypoglycemia (Phase 2)

Insulin Resistance (Early Phase 1)

Insulin Secretion (Phase 1)

Intestinal Failure (Phase 1/Phase 2)

Pancreatic Diseases (Phase 1)

Short Bowel Syndrome (Phase 1/Phase 2)

Urination Disorders (Early Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 41
  • # of Trial Organizations: 39

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue